How Often Does H. Pylori Cause Cancer?

Most people infected with H. pylori never develop cancer. The bacterium lives in the stomachs of over half the world’s population, yet only a fraction of those carriers go on to develop gastric malignancies. In a Japanese simulation study, the adjusted lifetime risk of gastric cancer for an infected man was about 17%, and for an infected woman about 8%, compared with roughly 1% and under half a percent, respectively, for uninfected people.¹ Those numbers reflect a country with unusually high gastric cancer rates; in much of Africa and South Asia, infection is widespread but cancer rates are far lower. What determines whether a decades-long infection stays harmless or turns dangerous is a tangle of bacterial genetics, host biology, diet, and timing that researchers are still working out.

The Global Picture

H. pylori is classified as a Group I carcinogen, the strongest category the World Health Organization uses. That label sometimes creates the impression that infection is a near-certain path to cancer. It is not. The bacterium is necessary for the vast majority of gastric cancers but far from sufficient on its own.² A recent global modeling study estimated that among people alive today, about 15.6 million will develop gastric cancer in their lifetimes, and roughly 76% of those cases are attributable to H. pylori.³ For noncardia gastric cancer specifically, the share is even higher: nested case-control studies suggest that H. pylori accounts for about 90% of those tumors worldwide.⁴

But 76% of gastric cancers being caused by the bacterium is a very different statement from 76% of infected people getting cancer. The denominator matters enormously. Billions of people carry H. pylori, and gastric cancer is diagnosed in fewer than a million people per year globally. In most populations, an infected person’s individual lifetime risk of stomach cancer sits somewhere in the low single digits. Where it climbs higher, as in Japan and parts of East Asia, country-specific factors like diet and prevalent bacterial strains play a role.

What Makes a Strain Dangerous

Not all H. pylori are created equal. The single biggest dividing line between more dangerous and less dangerous strains is whether they carry a gene called cagA. Strains that have it produce a protein, CagA, that the bacterium injects directly into the cells lining your stomach using a molecular syringe. Once inside, CagA hijacks growth and motility signals in the cell, pushing it toward the kind of uncontrolled behavior seen in cancer.⁵ CagA-positive strains are far more strongly associated with gastric cancer than CagA-negative ones.⁶

A second major virulence factor is a toxin called VacA, which damages the stomach lining in a different way. VacA causes visible damage to acid-producing cells and thins the protective mucus layer of the stomach.⁷ It also suppresses the local immune response by interfering with the activation of T cells, the immune cells that would otherwise help clear the infection. That immune suppression helps explain why infections persist for decades.⁸ In animal models, diets high in salt worsened the carcinogenic effects of CagA-positive strains dramatically. In one study using gerbils, every animal infected with a CagA-positive strain and fed a high-salt diet had developed stomach cancer by four months, compared with about 58% on a normal diet and none infected with a CagA-negative strain.⁹

Why Your Own Body Matters as Much as the Bacterium

Two people can carry identical strains of H. pylori for the same length of time and have completely different outcomes. A big reason is variation in human genes that control inflammation. One well-studied example involves the gene for interleukin-1-beta, a protein your body uses to drive inflammation and, separately, to reduce stomach acid. People who carry certain versions of this gene produce more interleukin-1-beta in response to H. pylori, which leads to more intense chronic inflammation and less acid in the stomach, both of which create an environment friendlier to cancer development.¹⁰ In one study, people who were infected with H. pylori and carried a high-risk version of a related gene had roughly 11 times the odds of developing the intestinal type of gastric cancer compared with uninfected non-carriers.¹¹

Diet amplifies or mutes the risk too. High salt intake has been consistently linked to worse outcomes in infected people, both in the animal work described above and in human epidemiological studies.¹² And there is growing evidence that other microbes in the stomach interact with H. pylori in ways that influence cancer risk. After H. pylori is eradicated, for instance, certain patients develop a stomach microbiome enriched in species like Fusobacterium and Neisseria that activate cancer-promoting pathways on their own and are associated with higher gastric cancer incidence.¹³

The Slow Cascade from Infection to Cancer

Stomach cancer from H. pylori does not appear suddenly. It typically follows a decades-long sequence of tissue changes that pathologists call the precancerous cascade: first, chronic inflammation of the stomach lining, then a gradual loss of the normal glands (atrophic gastritis), then replacement of stomach tissue with intestinal-type tissue (intestinal metaplasia), then increasingly abnormal cell growth (dysplasia), and finally invasive cancer.¹⁴ Most infected people stall somewhere in the first stage, chronic gastritis, and never progress further. A large Korean study of nearly 7 million people quantified how the infection pushes people through this sequence: H. pylori infection raised gastric cancer risk about sixfold overall, but about a third of that effect flowed through a precancerous intermediate called adenoma.¹⁵

That stepwise nature is actually good news, because it means there are multiple points along the way where the process can be interrupted. Persistent H. pylori infection roughly doubled the odds of intestinal metaplasia progressing, while eradication and other interventions can slow or reverse the early stages.¹⁶

The African Enigma

One of the longest-standing puzzles in gastric cancer research is why some of the populations with the highest H. pylori infection rates have some of the lowest gastric cancer rates. In many parts of sub-Saharan Africa, infection prevalence is above 70%, yet stomach cancer is comparatively rare. This pattern, first pointed out in the early 1990s and dubbed “the African Enigma,” has since been observed in parts of South Asia as well.¹⁷

Coevolution offers one compelling explanation. A study in two Colombian populations found that when the ancestral genetic backgrounds of the bacterium and the human host matched, as they did in coastal communities where both host and pathogen had predominantly African ancestry, gastric disease was mild. When the ancestral backgrounds were mismatched, as in mountain communities where Amerindian-ancestry people were infected with European-ancestry strains, gastric damage was severe. The statistical interaction between host and pathogen ancestry completely accounted for the difference in disease between the two regions.¹⁸ In other words, centuries of shared evolution between a population and its local strains may dampen the bacterium’s cancer-causing potential, while historical disruptions that introduced foreign strains into new host populations may heighten it. A genomic analysis of H. pylori strains in the Americas found that virulence genes had undergone especially strong selection in populations descended from these kinds of mismatches, potentially contributing to the region’s high gastric cancer burden.¹⁹

MALT Lymphoma, the Other Cancer

Gastric adenocarcinoma gets most of the attention, but H. pylori also drives a rarer cancer: MALT lymphoma of the stomach. This is a slow-growing cancer of immune tissue that develops in the stomach lining in response to chronic H. pylori stimulation of immune cells. The relationship between infection and this lymphoma is so direct that simply treating the infection with antibiotics causes the lymphoma to regress in roughly 60% to 80% of patients, and most of those remissions are durable.²⁰ That finding, first demonstrated in the early 1990s, remains one of the most striking examples in all of oncology of a malignant tumor being reversed by treating an infection.²¹ CagA appears to play a role here too: the protein can enter B cells (the immune cells that become cancerous in MALT lymphoma) and directly block their programmed cell death, promoting survival of abnormal clones.²⁰

Does Getting Rid of the Infection Help?

Yes, and substantially. A meta-analysis pooling data from multiple trials found that people who had their H. pylori eradicated had about half the rate of gastric cancer compared with untreated controls. The benefit held for asymptomatic carriers and for patients who had already had an early gastric cancer removed endoscopically.²² There is an important caveat, though: the protective benefit of eradication is greatest when it happens before the stomach lining has already sustained serious damage. Once atrophic gastritis or intestinal metaplasia has set in, antibiotics can reduce precancerous changes, but only in the earlier stages of the cascade.²³

Still, there is reason for optimism even for people with moderate damage. A prospective study following patients for up to 10 years after eradication found that atrophic gastritis in the stomach gradually and significantly improved in the eradicated group, eventually becoming indistinguishable from people who had never been infected. Intestinal metaplasia improved too, though it took longer, roughly three to five years to converge with the never-infected group.²⁴ The takeaway: earlier treatment is better, but later treatment still helps.

When H. pylori Might Actually Protect

In one of the more counterintuitive findings in gastric microbiology, H. pylori infection appears to lower the risk of a completely different cancer: adenocarcinoma of the esophagus. A meta-analysis found that infected people had about 44% lower odds of developing this type of esophageal cancer, and the protection was concentrated among carriers of CagA-positive strains.²⁵ The likely mechanism involves stomach acid. H. pylori infection, especially with virulent strains, tends to reduce acid production over time. Less acid reflux into the esophagus means less of the chronic irritation that drives the Barrett’s esophagus-to-cancer sequence.²⁶ This does not mean the infection is a net benefit; gastric cancer kills far more people worldwide than esophageal adenocarcinoma. But it does illustrate why simply eradicating H. pylori from every carrier on the planet is not as straightforward a calculation as it might seem.

Testing and Screening

If you are curious about your own infection status, several noninvasive tests exist. The urea breath test is the most accurate of the bunch, with a sensitivity above 90% in large systematic reviews.²⁷ Stool antigen tests are somewhat less sensitive but cheaper and easier to administer. Blood antibody tests are the least reliable for active infection, because antibodies can linger for years after the bacterium has been cleared, so they tell you whether you have ever been infected rather than whether you are infected now.²⁸

The question of who should be screened is more contested. In Japan, where gastric cancer is common, a national program offering H. pylori eradication has already been shown to be both cost-effective and life-saving, preventing hundreds of thousands of cancer cases and saving billions of dollars over several years.²⁹ Modeling in South Korea suggests that screening people as young as 15 and eradicating early would be highly cost-effective compared with relying on later endoscopic surveillance.³⁰ In lower-risk countries, population-wide screening is harder to justify on cost grounds alone, but individual testing makes sense for people with a family history of gastric cancer, those from high-prevalence regions, or anyone with persistent upper gastrointestinal symptoms.

The Vaccine That Does Not Exist Yet

Given that H. pylori infects billions and antibiotic resistance is rising, a vaccine would be a powerful tool. There is proof of concept that vaccination can prevent children from acquiring the infection in the first place.³¹ But despite more than 30 years of effort, no H. pylori vaccine has made it to market. The bacterium is an unusually difficult target: it has evolved elaborate immune-evasion strategies, it comes in genetically diverse strains across different regions, and the stomach is a challenging site for generating a lasting immune response.³² Some researchers are now turning to AI-driven approaches to design multi-target vaccines tailored to different strain populations, but these remain in early development.³³ For now, the practical options remain testing, antibiotic eradication when indicated, and surveillance of people at higher risk.

When Infection Starts May Matter

There is long-standing evidence that acquiring H. pylori in early childhood, rather than later in life, elevates the risk of eventually developing gastric cancer. A study of infected men found that those from larger families and of higher birth order, both proxies for crowded conditions favoring early transmission, had about double the odds of gastric cancer compared with infected men without those risk factors.³⁴ The logic is straightforward: more decades of chronic inflammation means more opportunity for the precancerous cascade to advance. However, a comparison of two Colombian populations with very different cancer rates found that the age of infection after the first year of life did not cleanly explain the gap. Bacterial virulence factors mattered more.³⁵ So timing of infection likely contributes to risk but does not override the effects of strain type and host genetics.